[go: up one dir, main page]

WO2009013075A3 - Markers for invasion in breast and lung carcinoma - Google Patents

Markers for invasion in breast and lung carcinoma Download PDF

Info

Publication number
WO2009013075A3
WO2009013075A3 PCT/EP2008/057606 EP2008057606W WO2009013075A3 WO 2009013075 A3 WO2009013075 A3 WO 2009013075A3 EP 2008057606 W EP2008057606 W EP 2008057606W WO 2009013075 A3 WO2009013075 A3 WO 2009013075A3
Authority
WO
WIPO (PCT)
Prior art keywords
invasion
markers
breast
lung carcinoma
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/057606
Other languages
French (fr)
Other versions
WO2009013075A2 (en
Inventor
Niall Barron
Isabella Bray
Martin Clynes
Padraig Doolan
Aisling Pierce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dublin City University
Original Assignee
Dublin City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dublin City University filed Critical Dublin City University
Publication of WO2009013075A2 publication Critical patent/WO2009013075A2/en
Publication of WO2009013075A3 publication Critical patent/WO2009013075A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to markers indicative of invasion in cancers, particularly breast and lung carcinomas. These markers find use in the diagnosis/prognosis of invasion (metastasis) and may thus be useful in identification of suitable treatment regiment for patients. The markers may also be of use in identifying potential therapeutic agents or targets for the prevention or reduction of invasion in cancer patients.
PCT/EP2008/057606 2007-06-19 2008-06-17 Markers for invasion in breast and lung carcinoma Ceased WO2009013075A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2007/0443 2007-06-19
IE20070443 2007-06-19

Publications (2)

Publication Number Publication Date
WO2009013075A2 WO2009013075A2 (en) 2009-01-29
WO2009013075A3 true WO2009013075A3 (en) 2009-03-19

Family

ID=39720541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057606 Ceased WO2009013075A2 (en) 2007-06-19 2008-06-17 Markers for invasion in breast and lung carcinoma

Country Status (1)

Country Link
WO (1) WO2009013075A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2728017B1 (en) 2007-11-19 2016-08-24 Celera Corporation Lung cancer markers and uses thereof
CN110850088B (en) * 2019-12-06 2021-08-20 四川大学华西医院 Use of GTF2IRD2 autoantibody detection reagent in the preparation of lung cancer screening kit
KR102280360B1 (en) * 2019-12-20 2021-07-23 주식회사 베르티스 A Composition for Diagnosing Cancer
CN114644687B (en) * 2022-04-07 2023-06-27 华中科技大学同济医学院附属协和医院 Polypeptide RBIP-21 capable of antagonizing RBM25 protein RNA binding activity and application thereof
CN116735894A (en) * 2023-06-14 2023-09-12 上海市胸科医院 Protein markers for identifying subtypes of non-small cell lung cancer and their applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009063A1 (en) * 1995-09-05 1997-03-13 Chiron Corporation Uses of tfpi inhibitor for treatment of cancer
US20020173465A1 (en) * 1997-02-06 2002-11-21 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009063A1 (en) * 1995-09-05 1997-03-13 Chiron Corporation Uses of tfpi inhibitor for treatment of cancer
US20020173465A1 (en) * 1997-02-06 2002-11-21 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
IVERSEN N ET AL: "Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation.", BRITISH JOURNAL OF HAEMATOLOGY SEP 1998, vol. 102, no. 4, September 1998 (1998-09-01), pages 889 - 895, XP002494981, ISSN: 0007-1048 *
IVERSEN NINA ET AL: "Elevated plasma levels of the factor Xa-TFPI complex in cancer patients.", THROMBOSIS RESEARCH 1 JAN 2002, vol. 105, no. 1, 1 January 2002 (2002-01-01), pages 33 - 36, XP002494984, ISSN: 0049-3848 *
KURER M A: "Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells", MOLECULAR BIOLOGY REPORTS ; AN INTERNATIONAL JOURNAL ON MOLECULAR AND CELLULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 34, no. 4, 19 December 2006 (2006-12-19), pages 221 - 224, XP019555169, ISSN: 1573-4978 *
LINDAHL A K ET AL: "Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease.", CANCER 15 OCT 1992, vol. 70, no. 8, 15 October 1992 (1992-10-15), pages 2067 - 2072, XP002494982, ISSN: 0008-543X *
LINDAHL AK ET AL: "High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer", ACTA CHIRURGICA SCANDINAVICA, SCANDINAVIAN UNIVERSITY PRESS, OSLO, NO, vol. 155, 1 January 1989 (1989-01-01), pages 389 - 393, XP009105301, ISSN: 0001-5482 *
OSTERGAARD P B ET AL: "An enzyme linked immunosorption assay for tissue factor pathway inhibitor.", THROMBOSIS RESEARCH 1 SEP 1997, vol. 87, no. 5, 1 September 1997 (1997-09-01), pages 447 - 459, XP002494983, ISSN: 0049-3848 *

Also Published As

Publication number Publication date
WO2009013075A2 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
EP1522594A3 (en) Methods and kits for investigating cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
EP1872124A4 (en) Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007143037A3 (en) Gene methylation in cancer diagnosis
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2010125566A3 (en) Markers for cancer detection
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007006408A3 (en) Methods and kits for predicting and monitoring direct response to cancer therapy
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2010093742A8 (en) Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP1365034A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
MX2009005058A (en) Methods of treating, diagnosing or detecting cancer.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2009013075A3 (en) Markers for invasion in breast and lung carcinoma
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08826619

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08826619

Country of ref document: EP

Kind code of ref document: A2